...
4/1/13 1pm | PUW3 |
| General discussion |
11/1/13 1pm | Levinsky | Joe | Maraviroc PK |
18/1/13 1pm | PUW4 | Andrezj | PKPD bridging of response between adults and children |
25/1/13 1pm | PUW3 | Lilia | Neutropenia following paediatric BMT |
1/2/13 1pm | PUW1 | Mirjam Trame | Use of PKPD modeling to guide HIV understanding and treatment |
8/2/13 1pm | PUW3 | Sami | Bioequivalence studies and genetic variability |
15/2/13 1pm | PUW1 | Liana | ErbB inhibition for PKD |
22/2/13 1pm | PUW3 | Alienor Berges (GSK) |
|
1/3/13 1pm | PUW4 | Rollo | CD4 reconstitution post BMT |
8/3/13 1pm | PUW3 | Eva | Neogent update |
15/3/13 1pm | PUW4 | Tafi | Dose individualisation in HIV/AIDS and TB patients on Efavirenz (EFV). |
22/3/13 1pm | PUW3 | Hui Ma | Genetic components to glucose-insulin response |
26/4/13 1pm | PUW3 | Sarit | FA and bioavailability |
10/5/13 1pm | PUW3 | Tafi | Common adverse drug reactions linked to HIV and/or TB medication: Lipodystrophy, Skin Hypersensitivity, CNS and Peripheral Neuropathy. |
28/5/13 1pm | PUW1 | Charlotte | Use of meta-analysis in evidence synthesis: an example based on dose selection for antibiotics (PAGE talk) |
31/5/13 1pm | PUW1 | Rollo | Modelling immune reconstitution in children post HSCT (PAGE talk) |
7/6/13 1pm | PUW3 | Julie | Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy (PAGE talk) |
21/6/13 1pm | PUW1 | Bruce Green | Therapeutic Drug Monitoring |